Comparative safety study on severe anemia by simeprevir versus telaprevir‐based triple therapy for chronic hepatitis C

ConclusionsPatients treated with simeprevir‐based triple therapy have a lower risk of the development of severe anemia than those treated with telaprevir. Moreover, ITPA genotype and age may be useful for individualizing treatment to reduce the risk of anemia‐related adverse effects.

http://onlinelibrary.wiley.com/resolve/doi?DOI=10.1111%2Fjgh.12945

Source: Journal of Gastroenterology and Hepatology - July 23, 2015 Category: Gastroenterology Authors: Eiichi Ogawa, Norihiro Furusyo, Eiji Kajiwara, Hideyuki Nomura, Akira Kawano, Kazuhiro Takahashi, Kazufumi Dohmen, Takeaki Satoh, Koichi Azuma, Makoto Nakamuta, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda, Jun Hayashi, Tags: Hepatology Source Type: research